SCHEMBL23728328

SCHEMBL23728328

[CH2]C(CO)C(CO)Cc1cccc(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.44
DRD2 P14416 1/20 0.42
DRD1 P21728 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
PKM P14618 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 2/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
MIF P14174 1/20 0.39
GRIA2 P42262 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enterodiol SCHEMBL120183 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL2641390 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL31171980 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL31171979 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL31171993 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL30334906 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL11271740 0.87 ENPP2 (0.52) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL2806235 0.76 TRPA1 (0.59) ENPP2DRD2TAAR1CYP3A4CYP1A2
SCHEMBL13165434 0.76 ENPP2 (0.41) ENPP2DRD2DRD1TAAR1CYP3A4
Enterodiol SCHEMBL2987870 0.74 OPRK1 (0.52) DRD2DRD1CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US disclosed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB ENPP2 657/4885DRD2 4611/4885DRD1 4755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.